ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Citing a strong customer pipeline and increasing demand for biologic drugs, Lonza says it will invest $936 million in mammalian cell manufacturing at its plants in Visp, Switzerland, and Portsmouth, New Hampshire. In Visp, the contract manufacturer will add six 20,000 L bioreactors by 2024, at a cost of $716 million. In Portsmouth, Lonza will spend $220 million to add up to eight 2,000 L bioreactors supporting clinical-to-commercial-scale manufacturing.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X